Skip to Content
David F Jarrard, MD

Contact Dr. Jarrard

E-mail:
jarrard@urology.wisc.edu

Phone:
(608) 262-0759

Mail:
UW Medical Foundation Centennial Building
1685 Highland Ave
MADISON, WI 53705-2281

David F Jarrard, MD

Vice Chair for Clinical Affairs
Professor of Urology
John Livesey Chair in Urologic Oncology

Education

  • MD, University of Virginia School of Medicine, Charlottesville, VA, 1989
  • Junior Residency in General Surgery, University of Chicago, Chicago, IL, 1989-1990
  • Residency in Urology, University of Chicago, Chicago, IL, 1990-1994
  • Fellow in Urologic Oncology, American Foundation for Urologic Disease, Johns Hopkins University, Baltimore, MD, 1994-1996

Clinical Specialties

Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment including robotics.

Research Interests

Dr. Jarrard has a joint appointment with the University of Wisconsin Comprehensive Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.

Dr. Jarrard's lab

Funding/Grants
  • The Induction of Cellular Senescence as Therapy for Advanced Prostate Cancer
    Funding Agency: Prostate Cancer Foundation
    Principal Investigator(s): David F Jarrard, MD
    More Information

Recent Publications
  • Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P, Devon ON, Tarrell RF, Frank I, Jarrard DF, Downs TM, Boorjian SA. Perioperative Blood Transfusion and Radical Cystectomy: Does Timing of Transfusion Affect Bladder Cancer Mortality? Eur. Urol. 2014 Sep 3.
    [PubMed ID: 25194909]
    More Information
  • Abel EJ, Wong K, Sado M, Leverson GE, Patel SR, Downs TM, Jarrard DF. Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS 2014 Apr-Jun; 18(2):282-7.
    [PubMed ID: 24960494, PMCID: 4035641]
    More Information
  • Yang B, Wagner J, Damaschke N, Yao T, Wuerzberger-Davis SM, Lee MH, Svaren J, Miyamoto S, Jarrard DF. A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. PLoS ONE 2014; 9(2):e88052.
    [PubMed ID: 24558376, PMCID: 3928145]
    More Information
  • Abel EJ, Bauman TM, Weiker M, Shi F, Downs TM, Jarrard DF, Huang W. Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. Hum. Pathol. 2014 May; 45(5):1092-9.
    [PubMed ID: 24746216, PMCID: 4134351]
    More Information
  • Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer 2013 Nov 15; 119(22):3992-4002.
    [PubMed ID: 24006289]
    More Information
  • Damaschke NA, Yang B, Bhusari S, Svaren JP, Jarrard DF. Epigenetic susceptibility factors for prostate cancer with aging. Prostate 2013 Dec; 73(16):1721-30.
    [PubMed ID: 23999928]
    More Information
  • Yang B, Wagner J, Yao T, Damaschke N, Jarrard DF. Pyrosequencing for the rapid and efficient quantification of allele-specific expression. Epigenetics 2013 Oct 1; 8(10):1039-42.
    [PubMed ID: 23973940, PMCID: 3891684]
    More Information
  • Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, Huang W, Jarrard DF. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 2013 Apr; 15(4):399-408.
    [PubMed ID: 23555185, PMCID: 3612912]
    More Information
  • Truong M, Yang B, Wagner J, Desotelle J, Jarrard DF. Analysis of promoter non-CG methylation in prostate cancer. Epigenomics 2013 Feb; 5(1):65-71.
    [PubMed ID: 23414321, PMCID: 3731941]
    More Information
  • Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW, Jarrard DF. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J. Urol. 2013 Jun; 189(6):2335-41.
    [PubMed ID: 23159584]
    More Information


webmaster@surgery.wisc.edu Copyright © 2014 The Board of Regents of the University of Wisconsin System